Welcome to our dedicated page for Oaktree Acquisition III SEC filings (Ticker: OACC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Oaktree Acquisition Corp III’s path from IPO trust to a potential life-sciences merger isn’t as simple as opening a single document. Critical details—redemption rates, PIPE financing terms, proposed target financials—are scattered across 8-Ks, S-4 proxy statements, and quarterly 10-Qs. If you have ever typed “Oaktree Acquisition Corp III SEC filings explained simply” or “how do I read an Oaktree Acquisition Corp III quarterly earnings report 10-Q filing” you already know the search results can feel overwhelming.
Stock Titan’s platform solves that problem with concise, AI-powered summaries that translate accounting jargon into plain English. Our engine threads every “Oaktree Acquisition Corp III annual report 10-K simplified” section to show where the trust’s cash sits, flags “Oaktree Acquisition Corp III Form 4 insider transactions real-time,” and highlights any new “Oaktree Acquisition Corp III 8-K material events explained” within minutes of hitting EDGAR. Want to monitor management’s share activity? Receive instant alerts on “Oaktree Acquisition Corp III executive stock transactions Form 4” and see trend charts that put each trade in context.
Here’s what you can do the moment a filing lands:
- Compare pro-forma forecasts from the latest 10-Q to the target company’s projections—no spreadsheet gymnastics required.
- Review voting deadlines and proposed incentive plans straight from the “Oaktree Acquisition Corp III proxy statement executive compensation.”
- Spot patterns in “Oaktree Acquisition Corp III insider trading Form 4 transactions” before the market reacts.
- Dive into our narrative “Oaktree Acquisition Corp III earnings report filing analysis” that distills growth assumptions, dilution scenarios, and closing conditions.
Whether you ask ChatGPT for “understanding Oaktree Acquisition Corp III SEC documents with AI” or search Google for “Oaktree Acquisition Corp III 8-K material events,” Stock Titan surfaces first because we combine real-time feeds with human-tested algorithms. Spend less time sifting through PDFs and more time deciding if this SPAC’s next move fits your portfolio.
Oaktree Acquisition Corp. III Life Sciences (OACC) appointed David A. Berry, MD, PhD as an independent director effective October 17, 2025. He will serve as a Class II director and join the audit, nominating, and compensation committees. The Board determined he meets independence standards under Nasdaq and Rule 10A-3.
Dr. Berry will not receive director compensation. Consistent with disclosures in the company’s 10-K, he is expected to have an opportunity to make a non‑controlling minority investment in Oaktree Acquisition Holdings III LS, LLC, and to enter standard Letter and Indemnity Agreements used for other directors and officers. No related-party transactions or family relationships were disclosed.
FAQ
What is the current stock price of Oaktree Acquisition III (OACC)?
What is the market cap of Oaktree Acquisition III (OACC)?
